Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05169970 · ClinicalTrials.gov registry record · Phase 2

A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer

A Phase 2 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
215
Enrollment target
7
Study locations

NCT05169970: Recruiting Phase 2 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT05169970 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 215 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (65% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05169970, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
215 participants
Enrollment target
7
Study locations

Study Summary

The researchers are doing this study to find out if stereotactic body radiation therapy (SBRT) without androgen deprivation therapy (ADT) is an effective treatment approach for people with unfavorable intermediate-risk prostate. The researchers will see whether SBRT can prevent participants' cancer from coming back and/or spreading to other parts of the body. In addition, they will look closely at how safe and effective it is to rely on Decipher test results for determining which patients would benefit from more extensive radiation treatments

Primary Outcome

Biochemical progression will be determined according to the established criteria of 2 ng/nl elevation of the PSA nadir level (nadir + 2 definition).

Conditions Studied

Interventions

  • RADIATION Stereotactic Body Radiation Therapy (SBRT)

Study Locations (7)

New York

  • Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale

Trial Details

FieldValue
Enrollment Target 215 participants
Start Date 2021-12-09
Est. Completion 2026-12
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What NCT05169970 shows while recruiting

NCT05169970 is an interventional study that assigns participants to a tested intervention. The registered 215 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (65% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic Body Radiation Therapy (SBRT) is the first listed.

NCT05169970 lists 7 locations in 2 states (New York, New Jersey).

Frequently Asked Questions

What is clinical trial NCT05169970 about?

NCT05169970 is a clinical study titled "A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer". The researchers are doing this study to find out if stereotactic body radiation therapy (SBRT) without androgen deprivation therapy (ADT) is an effective treatment approach for people with unfavorable intermediate-risk prostate. The researchers will see whether SBRT can prevent participants' cancer ...

What is the current status of trial NCT05169970?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 215 participants. The study started on 2021-12-09. Estimated completion is 2026-12.

What conditions does trial NCT05169970 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT05169970?

The interventions under investigation include: Stereotactic Body Radiation Therapy (SBRT) (RADIATION).

Who is sponsoring clinical trial NCT05169970?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05169970 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05169970's enrollment target sits among peer trials

215 214th of 735 higher than 522 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05134012 · 215 participants · Phase 3

    RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

  • NCT05197270 · 215 participants · Phase 1

    4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

  • NCT05230199 · 215 participants · NA

    Sensory Optimization of the Hospital Environment

  • NCT05473429 · 215 participants · NA

    Characterization of Nociception Phenotype in Individuals With Intellectual Disability

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05169970, the US trial registry maintained by the National Library of Medicine. NCT05169970 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.